---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-089068"
form_type: "8-K"
ticker: "CTSO"
cik: "0001175151"
company_name: "Cytosorbents Corp"
filed_at: "2024-08-14T23:59:59+00:00"
generated_at: "2026-05-31T09:15:41.410709+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# CytoSorbents Q2 product sales up 10%, operating loss halved; DrugSorb-ATR submission on track

## Summary
- Total revenue $9.9M (+5% YoY); product sales $8.8M (+10%); gross margins improved to 75%.
- Operating loss narrowed 48% to $3.4M from $6.6M; additional cost cuts expected to save $5M annually.
- CFO Kathleen Bloch retired; Peter Mariani appointed as new CFO effective August 14, 2024.
- On track to submit DrugSorb-ATR marketing applications to U.S. FDA and Health Canada this quarter.
- Secured $20M credit facility with Avenue Capital; cash and restricted cash $14.9M as of June 30, 2024.

## SEC filing metadata
- accession: 0001104659-24-089068
- form_type: 8-K
- ticker: CTSO
- cik: 0001175151
- company_name: Cytosorbents Corp
- filed_at: 2024-08-14T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1175151/000110465924089068/0001104659-24-089068-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1175151/000110465924089068/tm2421554d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-089068
- JSON: https://secwatch.observer/filing/0001104659-24-089068.json
- Plain text: https://secwatch.observer/filing/0001104659-24-089068.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.